Trump’s executive order on drug costs offers a win for pharma

The latest stories trending on MedCity News.

Editor's Pick

Top Story Trump's Executive Order on Prescription Drug Costs Delivers a Win for Pharma Companies The Trump administration aims to change the Medicare Drug Price Negotiation Program in a way that would delay when certain drugs can be selected for negotiation. Sponsored How To Make It Easier For Early Stage Life Science Companies to Grow Presented by Mercury and MedCity News A webinar on May 8th, sponsored by fintech business Mercury will explore how a banking platform approach could be a resource for the needs of entrepreneurs across biotech, diagnostics, and other life science companies. Sign up to learn more! Advanced Rate Extended! The Advanced Rate has been extended for MedCity INVEST and now ends Friday 4/18. Join us in Chicago, May 21-22, to hear from visionary healthcare leaders and connect with top investors. Final Call to Secure your ticket before prices do increase! Register Now to Save $300

Featured News

Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare Disease With No Approved Drugs Glycomine's lead program is an experimental treatment for PMM2-CDG, an ultra-rare enzyme deficiency often misdiagnosed as cerebral palsy. With encouraging results from an open-label Phase 2 study, the biotech startup is now preparing for a placebo-controlled test that could potentially support a regulatory submission. Healthcare's Robotic Renaissance: Meeting Future Demands From the operating room to the front desk, robotics are now being integrated into a variety of applications with the purpose of freeing up time and services for healthcare workers to do what they do best, patient care. How the Healthcare Industry Can Soften Blow from Medicaid Cuts By adopting a fresh approach that places the right people in the right programs, including AI-enabled enrollment, health plans, the healthcare industry will be in a better position to weather impending federal cuts – and maybe even end up better for it.

Video   Vaccine Makers Aren't Speaking Out Against RFK Jr. Earlier this year at the annual J.P. Morgan healthcare conference in San Francisco, Pfizer CEO Albert Bourla said his company would be at the vanguard fighting in favor of vaccines if Robert F. Kennedy Jr. took action against these treatments. Since then, the Texas measles outbreak has spread — and Kennedy has failed to encourage vaccines, instead stressing that they should be optional. Additionally, Peter Marks, the former head of the FDA's Center for Biologics Evaluation and Research, resigned this month, and he has gone on the record saying that vaccine misinformation reigns at Kennedy's HHS. MedCity News Senior Reporter Frank Vinluan reached out to Pfizer and other vaccine makers to comment on this issue, and the response has been radio silence — which is interesting considering Bourla's earlier comments.

Sponsored What Are the Best Medical Coding Outsourcing Companies? Presented by Global Healthcare Resource Outsourcing your medical coding can help ensure a healthy revenue cycle. Discover the best medical coding outsourcing companies and find the right one for you. Learn More

Resources

Pivot: Discussing the Impact of a Proposed HIPAA Security Update All healthcare entities storing or transferring patient health information needs to be aware of a proposed update to HIPAA tackling data encryption. Bryan Marlatt, chief regional officer at CyXcel, talks with us about the evolving threat landscape and what the proposed rule means for healthcare organizations. Listen now

MedCity News • PO Box 901 • New York, NY unsubscribe